Cite
HARVARD Citation
Charles‐Schoeman, C. et al. (2019). Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis & rheumatology. 71 (9), pp. 1450-1459. [Online].